Reviva Pharmaceuticals announced FDA recommendations for a second Phase 3 trial of brilaroxazine to gather more efficacy and safety data before NDA submission for schizophrenia treatment. The drug has shown a well-tolerated safety profile and broad efficacy in previous trials, with a one-year study confirming sustained benefits and minimal side effects. Reviva plans to start the RECOVER-2 trial in mid-2026 and recently raised $10 million in a public offering to fund development. The company reported a $19.9 million net loss for 2025 but holds $23 million in cash post-offering, supporting operations into early 2027.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
